Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
Andrei Havași, Simona Căinap, Ana Teodora Havasi, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 544-544
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma
Angie Bates, Kameron L. Klugh, Anna O. Galaeva, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 994-994
Open Access | Times Cited: 4
FT-Raman and FTIR spectroscopy as a tools showing marker of platinum-resistant phenomena in women suffering from ovarian cancer
Marta Kluz-Barłowska, Tomasz Kluz, Wiesław Paja, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Targeted therapy in high grade serous ovarian Cancer: A literature review
Kaitlyn Dinkins, Wade Barton, Lauren Wheeler, et al.
Gynecologic Oncology Reports (2024) Vol. 54, pp. 101450-101450
Open Access | Times Cited: 6
Patient‐derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin
Yuqing Zhao, Chen Wang, Wei Deng, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 6
The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial
Angeles Alvarez Secord, Sharyn N. Lewin, Colin G. Murphy, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 4
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
Trudy Janice Philips, Britt Erickson, Stefani N. Thomas
Frontiers in Oncology (2025) Vol. 14
Open Access
Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
Caixia Wang, Changsheng Peng, Chuan Xie
Open Medicine (2025) Vol. 20, Iss. 1
Open Access
Role of drug induced nuclear CTSL (nCTSL) in DNA damage response in cancer- therapeutic implications
Prabhu Thirsangu, Ling Jin, Upasana Ray, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Comparison of Hepatic Function and Chemotherapy-Induced Side Effects Between Pegylated Liposomal Doxorubicin (PLD), Topotecan (TOPO), and Gemcitabine in Platinum-Resistant Ovarian Cancer (PROC)
Radu Dragomir, Marina Adriana Mercioni, Șerban Negru, et al.
Journal of Personalized Medicine (2025) Vol. 15, Iss. 1, pp. 39-39
Open Access
Mechanistic insights into pachymic acid’s action on triple-negative breast Cancer through TOP2A targeting
Ming Liu, Li Zheng, Yang Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer
Connor Wang, Maria Gomez-Roas, Emily Hinchcliff
Advances in Oncology (2025)
Closed Access
Research Progress of c-Kit in Platinum-Resistant Ovarian Cancer
Shiwei Li, Xiaolan Ke, Ning Hu, et al.
Journal of Biosciences and Medicines (2025) Vol. 13, Iss. 02, pp. 404-412
Open Access
E3 ubiquitin ligase FBXW11-mediated downregulation of S100A11 promotes sensitivity to PARP inhibitor in ovarian cancer
Ligang Chen, Mingyi Wang, Yunge Gao, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101246-101246
Open Access
Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study
Yidong Zhou, Fei Tong, B. Jin, et al.
Journal of Gynecologic Oncology (2025) Vol. 36
Open Access
The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer
Radu Dragomir, Alina Gabriela Negru, Marina-Adriana Mercioni, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 470-470
Open Access
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance
Sara Polajžer, Katarina Černe
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2545-2545
Open Access
ABCB1 confers resistance to carboplatin by accumulating stem-like cells in the G2/M phase of the cell cycle in p53null ovarian cancer
Danbi Lee, Hyun-Seok Jeong, Sun‐Young Hwang, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
PARP inhibitors in ovarian cancer: mechanisms of resistance and implications to therapy
Sanat Kulkarni, N. Seneviratne, Çağla Tosun, et al.
DNA repair (2025), pp. 103830-103830
Open Access
Exploring the Mechanism of Matrine in Ovarian Cancer Treatment Utilizing GEO Database and Cellular Experiments
Fangfang Zhang, Huaidong Cheng
Research Square (Research Square) (2025)
Closed Access
An Overview of Artificial Intelligence in Gynaecological Pathology Diagnostics
Anthony M. Joshua, Katie E. Allen, Nicolas M. Orsi
Cancers (2025) Vol. 17, Iss. 8, pp. 1343-1343
Open Access
Expression of HECTD3 in Epithelial Ovarian Cancer and Its Effect on Platinum Resistance
云婷 周
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 1989-2001
Closed Access
Breaking barriers: CAR-NK cell therapy breakthroughs in female-related cancers
G. Ahmad, Samaneh Nouri, Amirhossein Mohammad Gholian, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 187, pp. 118071-118071
Closed Access
Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
Jin Lee, Tetsuo Mashima, Naomi Kawata, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 5, pp. 1307-1320
Open Access | Times Cited: 3
Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer
Xiaoyang Han, Yan Gao, Mei Jiang, et al.
Journal of Cancer (2024) Vol. 15, Iss. 11, pp. 3427-3440
Open Access | Times Cited: 2
PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
Chaohua Liu, Jiana Li, Fei Xu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top